Ventricular asynchrony predicts a better outcome in patients with chronic heart failure receiving cardiac resynchronization therapy  by Pitzalis, Maria Vittoria et al.
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PCardiac Resynchronization Therapy
entricular Asynchrony Predicts a Better
utcome in Patients With Chronic Heart Failure
eceiving Cardiac Resynchronization Therapy
aria Vittoria Pitzalis, MD, PHD, Massimo Iacoviello, MD, PHD, Roberta Romito, MD,
ietro Guida, MS, Elisabetta De Tommasi, MD, Giovanni Luzzi, MD, PHD, Matteo Anaclerio, MD, PHD,
inzia Forleo, MD, PHD, Paolo Rizzon, MD
ari, Italy
OBJECTIVES The aim of this study was to evaluate whether the clinical benefit of cardiac resynchronization
therapy (CRT) can be prospectively predicted by means of the baseline evaluation of left
ventricular asynchrony.
BACKGROUND The reverse remodeling associated with CRT is more evident in patients with severe heart
failure (HF) and left bundle branch block (LBBB) who have left ventricular asynchrony.
METHODS Baseline left ventricular asynchrony was assessed in 60 patients with severe HF and LBBB by
calculating the electrocardiographic duration of QRS and the echocardiographic septal-to-
posterior wall motion delay (SPWMD). Left ventricular size and left ventricular ejection
fraction (LVEF), mitral valve regurgitation, and functional capacity were also evaluated. The
progression toward HF (defined as a worsening clinical condition leading to a sustained
increase in conventional therapies, hospitalization, cardiac transplantation, and death) was
assessed during follow-up, as were the changes in LVEF after six months.
RESULTS During the median follow-up of 14 months, 16 patients experienced HF progression.
Univariate analysis showed that ischemic cardiomyopathy, changes in the QRS duration after
implantation, and SPWMD significantly correlated with events. At multivariate analysis, a
long SPWMD remained significantly associated with a reduced risk of HF progression
(hazard ratio: 0.91; 95% confidence interval: 0.83 to 0.99; p  0.05). An improvement in
LVEF was observed in 79% of the patients with a baseline SPWMD of 130 ms and in 9%
of those with an SPWMD of 130 ms (p  0.0001).
CONCLUSIONS Baseline SPWMD is a strong predictor of long-term clinical improvement after CRT in
patients with severe HF and LBBB. (J Am Coll Cardiol 2005;45:65–9) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.09.058American College of Cardiology Foundation
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where is increasing evidence supporting the routine use of
ardiac resynchronization therapy (CRT) in treating pa-
ients with electrocardiographic ventricular asynchrony (i.e.,
eft bundle branch block [LBBB] and severe heart failure
HF]) despite optimal medical treatment (1–4). Not all
atients have subjective and/or objective responses to CRT
5,6), and so there is a need for parameters other than
BBB that could prospectively identify the patients who
ould benefit most (5–12).
See page 70
We have previously demonstrated that the presence of a
elay in posterior wall contraction in comparison with the
eptum is a useful marker for selecting the patients who
enefit most in terms of post-CRT reverse remodeling
6,11), but the possibility of being able to identify patients
n whom the implantation of the device not only improves
From the Institute of Cardiology, University of Bari, Bari, Italy.p
Manuscript received June 4, 2004; revised manuscript received July 23, 2004,
ccepted September 20, 2004.entricular remodeling but also outcome would be a great
linical advantage.
We evaluated whether our proposed echocardiographic
easurement of left ventricular asynchrony can identify the
atients receiving CRT who have a better outcome (i.e., a
eduction in the progression of HF).
ETHODS
tudy population. Between June 2000 and September
003, we consecutively screened all of the patients referred
o our HF unit. Seventy-two patients had New York Heart
ssociation functional class III chronic HF of any origin,
BBB (QRS duration 130 ms) (4), and a left ventricular
jection fraction (LVEF) of 35%. We excluded patients if
heir conditions were not stable, if they had spontaneous or
rovoked angina or the need for revascularization proce-
ures (6), or if they had not been receiving optimal drug
herapy for at least three months. The study was approved
y the local ethics committee, and the procedures followed
ere in accordance with institutional guidelines. All of the
atients gave their written consent.
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Echocardiography-Guided Resynchronization and Prognosis January 4, 2005:65–9aseline evaluations. Between seven and three days before
mplantation, the patients underwent a clinical examination,
2-lead electrocardiography, mono- and two-dimensional
chocardiographic and Doppler evaluations, and a cardio-
ulmonary test.
Echocardiography recordings were made using a phased-
rray echo-Doppler system (Sonos 5500, Philips, Andover,
assachusetts) equipped with a 3-MHz transducer. After
esting for 10 min, the patients were examined in the left
ateral recumbent position using standard parasternal, short-
nd long-axis, and apical views. Intraventricular asynchrony
as evaluated by calculating the delay between the motion
f the septum and left posterior wall (septal-to-posterior
all motion delay [SPWMD]; in ms) (6). In two patients
ith myocardial infarction involving the septum wall, aki-
esia was observed, and no delayed contraction was regis-
ered. Therefore, we considered the SPWMD equal to zero.
s previously described, the intraobserver as well as the
nterobserver reproducibility of this parameter were very
igh (6). Baseline left ventricular end-diastolic diameter,
VEF, mitral (MR) and tricuspid (TR) regurgitation
quantified by arbitrary units) were also calculated.
The patients also underwent symptom-limited cycloer-
ometer exercise testing (10 W per min) with the assessment
f oxygen consumption (VO2) by means of mass spectrometry
Sensormedics System 2900, Anaheim, California); VO2 at
eak exercise was defined as the highest oxygen consumption
easured during the last 30 s of the symptom-limited exercise
est and expressed as ml/kg/min.
acemaker implantation. A total of 42 patients received a
iventricular pacemaker (Contak TR CHFD, Guidant, St.
aul, Minnesota; or InSync III, Medtronic, Minneapolis,
innesota), and 30 patients received a biventricular
ardioverter-defibrillator (Contak CD CHFD or Contak
enewal, Guidant; or InSync ICD or InSync Marquis,
edtronic; or Epic HF V-339, St. Jude Medical, St. Paul,
innesota). Left ventricular pacing was obtained trans-
enously using a unipolar lead with an over-the-wire system
Easytrak, Guidant; or Attain OTW, Medtronic; or Aes-
ula, St. Jude Medical) positioned into the lateral or
osterolateral cardiac vein as previously described (6). The
acing mode was programmed in DDD with the lower
Abbreviations and Acronyms
AUC  area under the curve
CI  confidence interval
CRT  cardiac resynchronization therapy
HF  heart failure
HR  hazard ratio
LBBB  left bundle branch block
LVEF  left ventricular ejection fraction
MR  mitral regurgitation
ROC  receiving-operating characteristic
SPWMD  septal-to-posterior wall motion delay
TR  tricuspid regurgitationate set at 50 beats/min. The atrioventricular interval was Tptimized using Doppler echocardiography (6). An elec-
rocardiogram was recorded within the first 2 h of CRT
ctivation.
ollow-up. Patients were followed up as outpatients in our
F clinic for at least six months. The clinical end point
onsidered was HF progression defined as death or hospi-
alization due to increased HF or symptoms of progression
upported by a change in medication for the treatment of
F, as indicated by any of the following: 50% increase in
he dose of oral medication, addition of new class of
edication, addition of intravenous medication, or intro-
uction of medication for HF, if not present at the time of
he event (13,14). The events were evaluated by a physician
ho was unaware of baseline intraventricular dyssynchrony.
Clinical examination and LVEF were evaluated after six
onths; LVEF was considered improved if it had increased
y 5% (15).
tatistical analysis. Data are shown as mean values  SD.
he continuous variables were compared using Student t
est for dependent (intragroup comparisons) and indepen-
ent (intergroup comparisons) variables, and frequencies by
eans of the Fisher’s exact test. Survival was analyzed using
he Cox proportional hazards model, and expressed as
azard ratios (HR) and 95% confidence intervals (CI). The
ariables significantly associated with the events at univari-
te analysis were included in a multivariate Cox regression
odel. The event-free curves were based on Kaplan-Meier
nalyses. The receiver-operating characteristic (ROC)
urves for sensitivity and specificity were constructed in
rder to evaluate the predictive values of the studied
ariables, and the areas under the curves (AUC) were
tatistically compared in order to estimate the accuracy of
he variables. A p value of0.05 was considered statistically
ignificant.
ESULTS
ixty-five of 72 screened patients met the enrollment
riteria; SPWMD was not available in three patients be-
ause of poor image quality, and the implantation failed in
wo cases. The patients’ baseline characteristics are shown in
able 1.
During the median follow-up of 14 months, four patients
ied of congestive HF, and 12 were hospitalized. The
atients with deteriorating HF more frequently had an
schemic etiology, a smaller reduction in QRS after CRT
QRS), a shorter baseline SPWMD, and more severe TR
Table 1). In 14 patients the significant functional and
emodynamic improvement led to diuretic therapy reduc-
ion.
At univariate analysis, only SPWMD, QRS, ischemic
ardiomyopathy, and TR significantly correlated with HF
rogression (Table 2). Multivariate analysis showed that
nly SPWMD remained significantly associated with HF
rogression (HR: 0.91; 95% CI: 0.83 to 0.99; p  0.05).
he Kaplan-Meier curves for the patients with an SPWMD
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January 4, 2005:65–9 Echocardiography-Guided Resynchronization and Prognosisbove or below the median value (130 ms) are shown in
igure 1.
After six months, LVEF was available in 51 patients
Fig. 2). Improvement was evident in 22 of 28 patients
79%) with baseline SPWMD 130 ms and only in 2 of 23
atients (9%) with SPWMD130 ms (p 0.0001). There
as a significant linear correlation between SPWMD and
VEF improvement (r: 0.69; p  0.001). Patients’ New
ork Heart Association functional class improved by at least
ne class in 22 of 28 patients (79%) with baseline SPWMD
130 ms and in 9 of 23 patients (39%) with SPWMD
130 ms (p  0.01).
The ROC curves showed that the AUC of SPWMD
Table 1. Baseline Clinical Characteristics
All Pati
Number 60
Age (yrs) 62 
Males/females 32/2
NYHA functional class 3 
Body mass index (kg/m2) 27 
Systolic arterial pressure (mm Hg) 114 
Ischemic cardiomyopathy (%) 22
PQ interval (ms) 203 
QRS duration (ms) 171 
QRS after implantation (ms) 41 
LVEF (%) 25 
LVEDD (cm) 6.8
SPWMD (ms) 147 
MR (a.u.) 2.7
TR (a.u.) 1.2
Concomitant therapy (%)
ACE inhibitors 80
AT2R antagonists 22
Beta-blockers 80
Digitalis 72
Diuretics 100
Aldosterone antagonists 88
Number 47
Peak VO2 (ml/min/kg) 10.8 
Mean values  SD. *p  0.05 vs. patients with events.
ACE angiotensin-converting enzyme; AT2R angiote
ventricular end-diastolic diameter; LVEF  left ventricular e
Heart Association; Peak VO2  oxygen consumption at pea
 tricuspid regurgitation.
able 2. Univariate Cox Regression Analysis
HR (95% CI) p Value
ge (yrs) 0.99 (0.94–1.04) NS
schemic cardiomyopathy 3.39 (1.25–9.18) 0.016
Q interval 0.99 (0.98–1.01) NS
RS duration (ms) 1.02 (0.99–1.04) NS
QRS (ms) 1.03 (1.01–1.05) 0.019
PWMD ( 10 ms) 0.90 (0.83–0.97) 0.006
VEF (%) 0.98 (0.89–1.09) NS
VEDD (cm) 1.58 (0.78–3.18) NS
R (a.u.) 1.02 (0.52–1.98) NS
R (a.u.) 2.44 (1.08–5.51) 0.03
eak VO2 (ml/kg/min) 0.93 (0.78–1.11) NSp
I  confidence interval; HR  hazard ratio.
Other abbreviations as in Table 1.0.90, 95% CI: 0.79 to 0.97) was significantly greater (p 
.001) than that of QRS duration (0.52, 95% CI: 0.38 to
.66) in predicting improvement.
ISCUSSION
he results of the present study help to answer one of the
ost compelling questions concerning the clinical useful-
ess of CRT in clinical practice: how to identify the patients
n whom the implantation of the device improves prognosis.
ntraventricular asynchrony (a SPWMD of 130 ms) can
rospectively identify the candidates for CRT in whom the
evice will reduce the progression of HF and improve
utcome.
Cardiac resynchronization therapy is a recognized emerg-
ng treatment for patients with HF, but the ideal candidate
s still a matter of discussion. Although clinical and func-
ional benefits have been reported, a wide QRS does not
eem to be specific in identifying a left ventricular asyn-
hrony suitable for pacing treatment.
The interest in this field has led to an increase in the
umber of papers focusing on the possible predictors of
enefit. Cardiopathy other than idiopathic, MR, and inter-
entricular contraction prolongation have been suggested to
e independently associated with clinical improvement (5).
lso the degree of QRS narrowing under biventricular
acing was associated with symptom and functional im-
Patients With
Events
Patients Without
Events
16 44
62  9 63  11
10/6 22/22
3  0 3  0
25  5 27  5
109  11 115  11
44 14*
199  24 204  34
179  30 168  18
31  20 45  20*
24  5 25  5
7.0  0.8 6.7  0.7
86  48 169  100*
2.8  0.9 2.7  0.9
1.4  0.6 1.0  0.6*
69 84
19 23
69 79
69 73
100 100
88 89
10 37
10.5  3.8 10.9  4.0
I receptor antagonists; a.u. arbitrary units; LVEDD left
fraction; MR  mitral regurgitation; NYHA  New York
ise; SPWMD  septal-to-posterior wall motion delay; TRents
10
8
0
5
11
32
22
21
5
0.7
96
0.9
0.7
3.9
nsin I
jectionrovement during follow-up (7). It is worth noting that the
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Echocardiography-Guided Resynchronization and Prognosis January 4, 2005:65–9bovementioned parameters are somehow related to the
resence of a ventricular dyssynchrony in the left ventricle.
he degree of left ventricular dyssynchrony measured by a
ariety of techniques (8–12) has been shown to be able to
uccessfully predict responders to resynchronization ther-
py. We have recently suggested that a long delay between
he displacements of the septum and the posterior wall
istinguishes the patients who will experience early post-
RT (6) and long-term reverse remodeling (11) from those
ho will not. In this study, we found that the presence of
chocardiographic left ventricular asynchrony predicts an
mprovement in LVEF of 5% with a sensitivity of 92%
nd a specificity of 78%.
Moreover, our results show that the benefit goes beyond
emodynamic improvement. When CRT is given to pa-
igure 1. Kaplan-Meier curves of patients with a septal-to-posterior wall
otion delay (SPWMD) of 130 ms and 130 ms.
igure 2. Left ventricular ejection fraction (LVEF) at baseline and after six
onths in patients with a septal-to-posterior wall motion delay (SPWMD)
f 130 ms (open circles) and 130 ms (closed circles). Date expressed
s mean values  SEM. *p  0.05 vs. baseline; †p  0.05 vs. patients with
n SPWMD of 130 ms.ients with an SPWMD of 130 ms, it reduces HF-
orsening events to a significantly greater extent than that
bserved in patients with less or no intraventricular asyn-
hrony. This finding should have a considerable impact on
linical practice, as the benefit can be prospectively pre-
icted in each individual patient before the decision to
mplant the device has been taken.
When baseline evaluation reveals a prolonged SPWMD,
RT is associated with an improved clinical outcome, but
ome patients with a short delay may also benefit from the
evice, which indicates the possible value of other echocar-
iographic methods of identifying asynchrony (8,9) or other
acing methods (16).
We found a high percentage of non-responders among
schemic patients. The lack of functional improvement was
ot due to the presence of ischemia, as provocative testing
id not induce ischemia before implantation. Therefore, it is
ossible that, in ischemic patients, LBBB may be associated
ith the presence of asynchrony in areas other than those
xplored by our parameter, and, if this is the case, CRT
imed at pre-exciting the lateral or posterolateral left ven-
ricular wall is not an adequate therapeutic strategy (17).
In line with the results of a previous study (7), a
ost-CRT reduction in QRS is also associated with a better
utcome. However, if we consider patients with the same
eduction, SPWMD provides further information concern-
ng who will not experience events during follow-up. Fur-
hermore, the echocardiographic evaluation of SPWMD
but obviously not the reduction in QRS) can be used for
atient selection.
In conclusion, baseline SPWMD is a strong predictor of
long-term improvement in post-CRT clinical outcome in
atients with severe HF and LBBB and can be proposed as
method of screening candidate patients.
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